Medical Letter on the CDC & FDA
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC & FDA
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Business & Finance
Cancer-, hepatitis-focused company affirms clinical progress, notes milestones
July 24th, 2005
ViRexx Medical Corp. (VIR) a company focused on immunotherapy and embolotherapy treatments for cancer and chronic hepatitis B and C, provided an update on its recent progress and expected milestones during the next 12 months. ViRexx Medical Corp. also announced the expansion of its intellectual property position with the issuance of an additional patent in Europe for its antibody targeting MUC-1 (BrevaRex MAb) associated malignancies, e.g. pancreatic, non small cell lung and breast cancers. Executing on its corporate and development strategy ViRexx has transformed its pipeline over the past months from pre-clinical stage to a broader pipeline of...
Source: Medical Letter on the CDC & FDA (2005-07-24)
|
